sunitinib malate market

Sunitinib Malate is a form of targeted therapy drug used for treating certain types of cancer. It works by halting or slowing down the development of cancer cells within the body. Also, sunitinib malate can slow the growth of new veins within the tumor. The anti-cancer medication is generally used with other cancer treatments, such as radiation therapy and chemotherapy, to improve the treatment results.

Sunitinib malate has been shown to improve the chances of progression-free survival and overall survival in patients with gastrointestinal stromal tumor (a type of stomach cancer) and renal cell carcinoma (a type of kidney cancer). In this blog post, we cover the medical uses of sunitinib malate and shed light on the growth drivers in the sunitinib malate market.

History of Sunitinib Malate

Sunitinib malate was first discovered at SUGEN, a drug discovery company that pioneered the development of protein kinase inhibitors. The drug was third in a series of compounds that impeded VEGFR kinases. Of the three compounds, SU5416 and SU6668 went into clinical trials for colon cancer in the late 1990s, whereas the FDA approved the usage of sunitinib malate for treating certain cancer types in January 2006.

Medical Uses of Sunitinib Malate

Gastrointestinal stromal tumor: This stomach cancer type doesn’t usually respond to commonly-used cancer treatment methods like chemotherapy or radiation. Sunitinib malate provides gastrointestinal stromal tumor patients with a new treatment option that can halt the further progression of the disease or even reverse it.

Meningioma: Sunitinib malate is being studied to treat meningioma, a primary central nervous system cancer that starts in the brain or spinal cord.

Also Read:  Conserving Soil & Its Nutrients With Mulching Materials Market

Pancreatic neuroendocrine tumors: This is a group of cancers that can arise in the hormone-producing cells of the pancreas. The USFDA has permitted sunitinib malate market key players to use the drug to treat pancreatic neuroendocrine tumors that surgery can’t remove.

Renal cell carcinoma: Renal cell carcinoma has been approved for treating renal cell carcinoma, a common type of kidney cancer.

Market Analysis and Growth Drivers

The market for sunitinib malate was valued at USD 105.22 million in 2022 and is expected to grow at a CAGR of 10.60%, generating a revenue of USD 278.54 million by 2032.

Utilizing sunitinib malate as a target therapy drug for cancer treatments has several benefits, including reduced toxicity and better results than traditional methods. The rising prevalence of different types of cancers and increasing adoption of target therapies in cancer treatments are expected to boost the sunitinib malate market demand.

Personalized cancer treatments, based on specific genetics and molecular characteristics, are designed to meet the particular requirements of individual patients. Sunitinib malate is generally used with other cancer therapy treatments to develop personalized treatment plans for individual patients. Using the drug with other treatment options will drive the market’s growth.

Pancreatic Neuroendocrine Tumor Segment Is Expected to Witness the Highest Growth

Pancreatic Neuroendocrine Tumor (PNET) is anticipated to witness the fastest growth over the forecast period. It is an uncommon type of pancreatic cancer that leads to the development of endocrine cells in the pancreas. PNET usually doesn’t react to conventional treatment methods such as chemotherapy. The FDA has approved sunitinib malate for the treatment of metastatic PNET. This is anticipated to create a favorable environment for the segment’s rise in the sunitinib malate market.

Also Read:  Cast Stretch Films Market: A Cost-Effective Alternative to Specific Industry Needs

Recent Developments

In September 2022, biotechnology company CytoReason announced a multi-year collaboration with American pharmaceutical company Pfizer. With the partnership, Pfizer aims to leverage CytoReason’s AI technology for activities related to drug development.

In January 2023, clinical-stage biopharmaceutical company CinCor Pharma was acquired by AstraZeneca. CinCor develops novel therapeutics for treating hypertension and other cardio-renal diseases.

Conclusion

Sunitinib malate is an anti-cancer medication that restricts the activity of specific proteins that lead to the growth and proliferation of cancer cells. The past few years have experienced significant advances in cancer treatment, and sunitinib malate has been a major driver in that progress. The sunitinib malate market sales are expected to rise with the development of innovative drug development systems.

By Ankita Padiyar

Ankita Padiyar likes to play with words! She has been working in the content industry, with expertise in SEO content, social media content, website content, blogs, and articles for over 5 years. In addition to content writing, Ankita is a content publisher too, with hands-on experience with different CMSs. She works closely with B2B and B2C companies delivering engaging content that converts viewers into customers. She believes in "Dream Big" and thrives to achieve those dreams. When she isn’t writing, you can find her spending quality time with her 2-year toddler. Also, in her free time, she loves to explore new places. Don’t miss connecting with her on LinkedIn for networking!